Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

SNES

SenesTech Inc

Nov 19 • 04:00PM ET

2.55

-0.21 -7.61 %

Basic Materials • Specialty Chemicals • USA • NASD

Peers: MOS DD SMG CF FMC NTR ROG AVD ICL ENFY

| Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-3.65	Insider Own	4.25%	Shs Outstand	5.22M	Perf Week	-14.72%
Market Cap	13.22M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	-0.03%	Shs Float	4.97M	Perf Month	-31.64%
Enterprise Value	5.65M	PEG	-	EPS next Q	-0.30	Inst Own	8.96%	Short Float	1.19%	Perf Quarter	-43.33%
Income	-5.83M	P/S	5.75	EPS this Y	69.19%	Inst Trans	3.80%	Short Ratio	0.61	Perf Half Y	-2.67%
Sales	2.30M	P/B	1.17	EPS next Y	59.34%	ROA	-61.18%	Short Interest	0.06M	Perf YTD	-22.96%
Book/sh	2.17	P/C	1.29	EPS next 5Y	53.00%	ROE	-77.79%	52W High	6.24 -59.13%	Perf Year	1.34%
Cash/sh	1.98	P/FCF	-	EPS past 3/5Y	82.90% 78.31%	ROIC	-42.04%	52W Low	1.30 96.15%	Perf 3Y	-99.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	45.73% 66.99%	Gross Margin	58.32%	Volatility	8.35% 8.30%	Perf 5Y	-99.92%
Dividend TTM	-	EV/Sales	2.46	EPS Y/Y TTM	69.81%	Oper. Margin	-255.58%	ATR (14)	0.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.73	Sales Y/Y TTM	39.37%	Profit Margin	-253.54%	RSI (14)	29.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.75	EPS Q/Q	86.59%	SMA20	-20.52%	Beta	0.24	Target Price	10.00
Payout	-	Debt/Eq	0.24	Sales Q/Q	43.15%	SMA50	-34.11%	Rel Volume	1.51	Prev Close	2.76
Employees	23	LT Debt/Eq	0.22	Earnings	Nov 10 AMC	SMA200	-28.22%	Avg Volume	96.98K	Price	2.55
IPO	Dec 08, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	20.00% -1.43%	Trades		Volume	146,168	Change	-7.61%

Nov-11-25 09:00AM	SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve Rat Birth Control (PR Newswire) -8.19%
12:04AM	SenesTech Inc (SNES) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion (GuruFocus.com)
Nov-10-25 04:05PM	SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA (PR Newswire)
12:00PM	SenesTech's Evolve Rat Birth Control Now Available Online at Lowes.com (PR Newswire)
Nov-07-25 07:27AM	SenesTech Inc (SNES) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +11.51%
05:25PM	Loading…
Nov-06-25 05:25PM	Celanese (CE) Beats Q3 Earnings Estimates (Zacks) -5.59%
Nov-05-25 08:10AM	Green Plains Renewable Energy (GPRE) Q3 Earnings Top Estimates (Zacks)
Nov-04-25 06:35PM	Ashland (ASH) Q4 Earnings Lag Estimates (Zacks) -6.08%
Nov-03-25 04:15PM	SenesTech to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025 (PR Newswire)
Oct-31-25 07:05AM	Linde (LIN) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-13-25 08:00AM	Swampscott Launches Pilot of SenesTech's Innovative Rat Birth Control at Firehouse and Local School (PR Newswire) +7.03%
Sep-17-25 04:15PM	SenesTech to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 (PR Newswire)
Sep-10-25 08:00AM	SenesTech's Evolve Rat Birth Control Now Available Online at HomeDepot.com (PR Newswire)
Sep-02-25 08:00AM	SenesTech's Evolve Deployments Expanded to Additional Chicago Neighborhoods (PR Newswire)
Aug-18-25 04:15PM	SenesTech to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025 (PR Newswire)
03:41AM	Loading…
Aug-08-25 03:41AM	SenesTech Inc (SNES) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion (GuruFocus.com) -12.99%
Aug-07-25 04:05PM	SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins (PR Newswire)
Aug-05-25 07:10PM	SenesTech Announces Closing of Warrant Exercise for $6.3 Million in Gross Proceeds (PR Newswire) -12.85%
08:00AM	SenesTech Announces Warrant Exercise for $6.3 Million in Gross Proceeds (PR Newswire)
Jul-31-25 04:15PM	SenesTech to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (PR Newswire)
Jul-01-25 05:46PM	SenesTech Announces Closing of Warrant Exercise for $4.4 Million in Gross Proceeds (PR Newswire)
08:00AM	SenesTech Announces Warrant Exercise for $4.4 Million in Gross Proceeds (PR Newswire)
Jun-26-25 08:00AM	SenesTech's Evolve Rodent Birth Control Proven in Urban Rodent Hotspots from Hong Kong to San Francisco (PR Newswire) +30.94%
Jun-25-25 08:00AM	SenesTech and Irvine Campus Housing Authority Conclude Successful Field Trial of Evolve Rat Birth Control at UC Irvine (PR Newswire)
Jun-13-25 08:00AM	Baltimore Expands Use of Evolve Rodent Birth Control Following Successful Pilot (PR Newswire) +21.43%
Jun-11-25 08:00AM	SenesTech Announces Bradley Caldwell, Inc. as New U.S. Distributor for Evolve Rodent Fertility Control Products (PR Newswire)
May-27-25 04:15PM	SenesTech to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 (PR Newswire)
May-09-25 03:47AM	SenesTech Inc (SNES) Q1 2025 Earnings Call Highlights: Evolve Product Line Drives Revenue Surge ... (GuruFocus.com) +8.18%
May-08-25 04:05PM	SenesTech Reports First Quarter 2025 Financial Results 40% Revenue Growth in Evolve, Record Gross Profit Margins of 65%, and Continued Progress Toward Profitability (PR Newswire)
May-07-25 09:00AM	SenesTech Announces Exclusive Distribution Agreement and Initial Order for Evolve Soft Bait in Indonesia (PR Newswire)
04:15PM	Loading…
May-01-25 04:15PM	SenesTech to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 (PR Newswire) +8.11%
Apr-17-25 09:00AM	SenesTech's Evolve Deployed in Chicago Neighborhoods (PR Newswire)
Mar-31-25 04:15PM	SenesTech to Participate in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025 (PR Newswire)
Mar-13-25 03:09AM	SenesTech Inc (SNES) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion (GuruFocus.com)
Mar-12-25 04:05PM	SenesTech Announces Record Fourth Quarter and Full Year 2024 Financial Results with 70% Quarterly Revenue Growth; Gross Profit Margins of 61%; Reduction in Operating Expenses; and Dramatic Improvement in Adjusted EBITDA (PR Newswire)
Mar-10-25 08:00AM	SenesTech Announces Warrant Exercise for $1.1 Million in Gross Proceeds (PR Newswire) -21.93%
Mar-06-25 04:15PM	SenesTech to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Wednesday, March 12, 2025 (PR Newswire)
Feb-25-25 09:25AM	SenesTech Expands its Rapidly Growing Global Footprint and Clears Major Regulatory Hurdle, Paving the Way for Use in Australia and New Zealand (PR Newswire) +5.77%
Feb-18-25 08:45AM	SenesTech Expands into Warehousing and Distribution Sector with Multi-Pallet Initial Shipment of Evolve Rodent Birth Control (PR Newswire)
Feb-10-25 09:20AM	SenesTech Expands E-Commerce Presence with Evolve Rodent Birth Control Now Available on TractorSupply.com (PR Newswire) -8.57%
Feb-04-25 11:30AM	SenesTech Expands Global Footprint for Evolve Rodent Birth Control: Signs Letter of Intent with SMark to Enter Indian Rodent Pest Control Market (PR Newswire) +8.60%
Jan-21-25 08:00AM	Baltimore Adopts Evolve Rodent Birth Control for Integrated Pest Management Targeting Rodent Overpopulation (PR Newswire) +11.61%
Jan-14-25 08:00AM	Bug Off Pest Control Center of New York City to Supply New York City with Evolve (PR Newswire)
Jan-10-25 04:15PM	Joshua M. Moss Joining the SenesTech Board of Directors (PR Newswire) -6.60%
Nov-13-24 02:22AM	SenesTech Inc (SNES) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion (GuruFocus.com) -7.12%
Nov-12-24 04:05PM	SenesTech Announces Third Quarter 2024 Financial Results (PR Newswire) -9.18%
09:00AM	SenesTech Launches Evolve Rodent Birth Control on Walmart Marketplace (PR Newswire)
Nov-06-24 10:36AM	SenesTech (SNES): Why Small Positions May Not Be the Safe Bet You Think (Insider Monkey) +8.37%
Nov-05-24 04:15PM	SenesTech to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (PR Newswire)
Oct-31-24 08:30AM	Evolve Registered in Hong Kong; Offering a Revolutionary Non-Lethal Rodent Control Solution (PR Newswire)
Oct-09-24 06:03PM	SenesTech Inc (SNES) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Oct-08-24 09:00AM	New York City to Pursue Rat Contraception Pilot Program (PR Newswire)
Sep-23-24 04:15PM	SenesTech to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (PR Newswire) +20.83%
Aug-23-24 04:00PM	SenesTech Announces Closing of Warrant Exercise for $2.3 Million in Gross Proceeds (PR Newswire) -15.46% -9.76%
Aug-08-24 04:05PM	SenesTech Announces Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 04:15PM	SenesTech to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (PR Newswire) -5.26%
Jul-31-24 08:00AM	IBN Announces Latest Episode of The GotStocks Podcast featuring Joel Fruendt, CEO of SenesTech Inc. (GlobeNewswire)
Jul-23-24 11:30AM	SenesTech Announces Reverse Stock Split (PR Newswire) -24.25%
Jun-26-24 09:00AM	SenesTech's Evolve Fertility Control Solution for Rats To Be Deployed in the U.S. Virgin Islands (PR Newswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
May-30-24 12:10PM	SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon (Zacks)
May-23-24 09:00AM	SenesTech to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire) -7.56%
May-22-24 09:00AM	SenesTech Launches Evolve Fertility Control Solution for Rats on Amazon, the World's Largest Online Retailer (PR Newswire) +8.09%
May-20-24 09:46AM	Should You Add SenesTech (SNES) to Your Portfolio? (Insider Monkey)
May-12-24 09:32AM	SenesTech, Inc. (NASDAQ:SNES) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	SenesTech Announces First Quarter 2024 Financial Results (PR Newswire) +9.06% -26.19%
May-02-24 04:15PM	SenesTech to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 (PR Newswire) +9.52%
09:00AM	SenesTech Launches Evolve Mouse (PR Newswire)
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 09:00AM	SenesTech to Present at the Emerging Growth Conference on April 3, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Mar-26-24 09:00AM	SenesTech Signs Wilco Distributing for Evolve and ContraPest Distribution in Agriculture and Professional Rodent Pest Management Market (PR Newswire)
Mar-06-24 07:00AM	Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire)
Mar-05-24 09:00AM	SenesTech to Present at the Emerging Growth Conference on March 6, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
Feb-24-24 08:15AM	SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-21-24 04:05PM	SenesTech Announces 2023 Financial Results (PR Newswire) +8.49% -19.84%
Feb-20-24 10:17AM	SenesTech (SNES) Expands in the Netherlands With Q-chem Deal (Zacks)
Feb-15-24 04:15PM	SenesTech to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Wednesday, February 21, 2024 (PR Newswire)
09:00AM	SenesTech Announces Exclusive Distribution Agreement for Evolve Soft Bait in The Netherlands (PR Newswire)
Feb-12-24 09:00AM	SenesTech Approved as Vendor for All Ace Hardware Stores (PR Newswire) +12.26%
Feb-08-24 09:00AM	SenesTech Announces Exclusive Distribution Agreement for Evolve Soft Bait in Australia and New Zealand (PR Newswire) -8.93%
Feb-05-24 09:00AM	SenesTech Announces Exclusive Distribution Agreement and Initial Order for Evolve Soft Bait in Singapore (PR Newswire) +18.93%
Jan-29-24 09:00AM	SenesTech Signs Poppe Enterprises for Evolve Distribution in Grain Management Market (PR Newswire) +7.55%
Jan-23-24 09:55AM	Senestech, Inc. (SNES) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) +26.89%
09:00AM	SenesTech to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire)
Jan-09-24 10:50AM	SenesTech's (SNES) New Partnership to Broaden Evolve's Scope (Zacks)
Jan-08-24 09:00AM	SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications (PR Newswire) +5.83%
Jan-02-24 09:00AM	SenesTech Signs Expanded Distribution Agreement for Evolve Soft Bait Sales into the United Arab Emirates (UAE) (PR Newswire) +25.98%
Jan-01-24 12:00PM	All You Need to Know About Senestech, Inc. (SNES) Rating Upgrade to Buy (Zacks)
Dec-19-23 08:20AM	SenesTech (SNES) Likely to Expand Into China With New Deal (Zacks) -5.73%
Dec-18-23 09:00AM	SenesTech Announces Exclusive Distribution Agreement and Initial Order for Evolve Soft Bait in Hong Kong and Macau (PR Newswire) +19.70%
Dec-14-23 09:00AM	SenesTech Receives Substantial Orders for EVOLVE Soft Bait (PR Newswire) +34.38%
Dec-05-23 08:17AM	IBN Announces Latest Episode of The Stock2Me Podcast featuring Joel Fruendt, President & CEO of SenesTech Inc. (GlobeNewswire) -15.76%
Dec-04-23 09:00AM	SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations (PR Newswire)
Nov-29-23 01:45PM	SenesTech, Inc. Announces Closing of $5.0 Million Public Offering (PR Newswire)
Nov-28-23 09:24AM	Why Is SenesTech (SNES) Stock Down 36% Today? (InvestorPlace) -50.53%
Nov-27-23 06:30PM	SenesTech, Inc. Announces Pricing of $5.0 Million Public Offering (PR Newswire) -13.36%
04:01PM	SenesTech Launches EVOLVE Soft Bait Fertility Solution in California-based Ace Hardware Franchise Locations (PR Newswire)

SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations. The firm focuses on rat populations through fertility control. It offers its ContraPest product to residential and commercial sectors such as animal, structural, and food markets. The company was founded by Loretta P. Mayer and Cheryl A. Dyer on July 27, 2004 and is headquartered in Phoenix, AZ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leach Jacob Steven	Director	Nov 18 '25	Sale	2.71	62	168	0	Nov 19 07:48 PM
Szot Matthew K	Director	Nov 14 '25	Sale	2.75	1	3	0	Nov 17 03:00 PM

Open in Screener

CVKD

Cadrenal Therapeutics Inc

Nov 19 • 04:00PM ET

11.26

-0.67 -5.61 %

Healthcare • Biotechnology • USA • NASD

CVKD Cadrenal Therapeutics Inc daily Stock Chart

Peers: ABBV JNJ MRK PFE LLY AMGN BMY REGN GILD VRTX

| Held by: VTI VXF IWC DFSU

Index	-	P/E	-	EPS (ttm)	-8.01	Insider Own	25.96%	Shs Outstand	2.06M	Perf Week	-8.00%
Market Cap	23.37M	Forward P/E	-	EPS next Y	-5.42	Insider Trans	-7.81%	Shs Float	1.54M	Perf Month	-14.73%
Enterprise Value	19.51M	PEG	-	EPS next Q	-1.21	Inst Own	5.50%	Short Float	1.84%	Perf Quarter	-9.56%
Income	-14.39M	P/S	-	EPS this Y	27.03%	Inst Trans	4.36%	Short Ratio	1.14	Perf Half Y	-28.28%
Sales	0.00M	P/B	8.48	EPS next Y	14.91%	ROA	-328.18%	Short Interest	0.03M	Perf YTD	-22.29%
Book/sh	1.33	P/C	6.05	EPS next 5Y	-	ROE	-468.03%	52W High	22.90 -50.83%	Perf Year	-28.09%
Cash/sh	1.86	P/FCF	-	EPS past 3/5Y	-0.45% -	ROIC	-525.99%	52W Low	8.74 28.84%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.65% 7.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-9.80%	Oper. Margin	-	ATR (14)	0.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.06	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.95	EPS Q/Q	39.76%	SMA20	-10.08%	Beta	1.10	Target Price	45.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-14.50%	Rel Volume	0.58	Prev Close	11.93
Employees	4	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	SMA200	-22.15%	Avg Volume	24.95K	Price	11.26
IPO	Jan 20, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	15.48% -	Trades		Volume	14,410	Change	-5.61%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

Nov-19-25 08:00AM	Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award (GlobeNewswire) -5.61%
Nov-17-25 03:00PM	Why the underdog mindset could be your business superpower (Yahoo Finance Video)
Nov-10-25 09:00AM	Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-25 01:27AM	Cadrenal Therapeutics, Inc. (Zacks)
Sep-29-25 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 (GlobeNewswire)
05:36AM	Loading…
Sep-16-25 05:36AM	Cadrenal Therapeutics acquires eXItheras Factor XIa inhibitors (Pharmaceutical Technology)
Sep-15-25 08:00AM	Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors (GlobeNewswire)
Aug-11-25 08:00AM	Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Aug-05-25 06:00AM	Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis (Business Wire) +23.72%
Jun-12-25 08:00AM	Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients (Business Wire)
Jun-04-25 08:00AM	Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 (Business Wire) +13.15%
May-15-25 07:30AM	Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness (Business Wire) +7.07%
May-08-25 08:00AM	Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Apr-17-25 09:40AM	Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq (Business Wire)
Apr-03-25 08:00AM	Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences (Business Wire)
04:05PM	Loading…
Mar-13-25 04:05PM	Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin (Business Wire) +9.40%
Mar-05-25 07:28AM	Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin (Medical Device Network)
Mar-04-25 08:00AM	Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD (Business Wire)
Feb-06-25 09:00AM	Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin (Business Wire)
Feb-05-25 09:00AM	Cadrenal Therapeutics to Present at BIO CEO & Investor Conference (Business Wire)
Jan-09-25 08:44AM	Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-31-24 08:00AM	Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications (Business Wire)
Dec-18-24 09:00AM	Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings (Business Wire) +13.19%
Nov-19-24 09:00AM	Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook (PR Newswire) -7.29%
Nov-12-24 09:00AM	CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS (PR Newswire)
Nov-07-24 09:00AM	CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE (PR Newswire)
Nov-01-24 08:00PM	Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds (PR Newswire) -18.86%
Oct-24-24 09:00AM	Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility (PR Newswire) +17.97%
Oct-23-24 09:00AM	CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM (PR Newswire)
Sep-23-24 04:15PM	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference (PR Newswire) -12.17% +16.94%
01:00PM	Loading…
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE) +17.85%
Aug-22-24 09:00AM	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients (PR Newswire) -5.52%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 09:00AM	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients (PR Newswire) +19.12%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-14-24 09:00AM	Cadrenal Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-12-24 05:07PM	Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now (Insider Monkey) +13.67%
Aug-07-24 11:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update (PR Newswire)
Aug-06-24 09:00AM	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs (PR Newswire)
Jul-17-24 09:00AM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 04:15PM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 (PR Newswire) +6.34%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-03-24 09:00AM	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients (PR Newswire) +5.45%
May-23-24 09:00AM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire)
May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire) -5.34%
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire) +8.70%
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.